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Consumer Prices for Surgical
Management of Ankle Arthritis:
Limited Availability and Wide
Variability
Abstract
Background: Healthcare costs for the surgical management of
ankle arthritis continue to rise. Patients are generally unaware of
the prices of the services they use. Understanding the costs
associated with surgical management of ankle arthritis is an
important facet of patient care. The purposes of this study were to
(1) determine the access to the surgical cost of total ankle
arthroplasty (TAAs) and ankle arthrodesis and (2) the variability of
the price between the two procedures.
Methods: Fifty foot and ankle centers (25 academic, 25 private)
that perform TAAs and ankle arthrodeses were contacted using a
standardized patient script. The described patient was a 63-year-
old man who had failed conservative treatment of ankle arthritis.
Each institution was contacted up to three times in an attempt to
obtain a full-bundled surgical quote for a TAA and an ankle
arthrodesis.
Results: Twenty-one centers (42%, 14 academic, 7 private) were
able to provide a quote for a TAA and an ankle arthrodesis. The
mean bundled price for a TAA was $50,332 (SD6 $25,744), with
the mean academic and private center quote being $56,529 and
$37,937, respectively. The mean bundled price for an ankle
arthrodesis was $41,756 (SD 6 $26,033), with the mean
academic and private center quote being $48,116 and $29,037,
respectively. No statistically significant difference was found
between the bundled prices for TAA and ankle arthrodesis.
Discussion: This study demonstrated limited availability of
consumer prices for TAA and ankle arthrodesis. When comparing
different institutions for surgical management of ankle arthritis,
there was a wide range of quotes for both TAA and ankle
arthrodesis. When comparing the choice of surgical management
for ankle arthritis, no statistically significant difference was
observed in price between TAA and ankle arthrodesis.
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End-stage ankle arthritis is anincreasingly common detrimen-
tal pathology that can lead to notable
physical disability.1 In the United
States alone, there are an estimated
50,000 new cases of ankle arthritis
diagnosed every year.2 With this
growing medical and financial bur-
den, the surgical management of the
disease is becoming more relevant
to both the orthopaedic surgeon and
the patient. Currently, the two most
common surgical modalities used to
treat advanced ankle arthritis are
either an ankle arthrodesis or a total
ankle arthroplasty (TAA). Although
arthrodesis of the tibiotalar joint
has historically been the traditional
treatment for advanced ankle ar-
thritis, a study using the Medicare
population database concluded that
the volume of TAAs being performed
increased by 1000% between 1991
and 2010.3
Given the increasing volume of
surgeries for ankle arthritis, the
financial burden of managing this
pathologywill continue to grow.This
will likely mirror the overall increas-
ing health expenditures expected at
the national level. The Centers for
Medicare and Medicaid Services
reported that US healthcare spending
increased by 4.3% in 2016, to reach
$3.3 trillion. This equates to $10,384
per person or 17.9% of gross do-
mestic product.4 With a projected
annual average growth rate of 5.6%,
American national health expenditures
are expected to reach 19.9% of GDP
by 2025.5
A potential solution to mitigate
rising healthcare costs is for patients
to assume greater responsibility in
deciding where to seek care and to
consider pricing when choosing a
provider and treatment.6-8 As with
any purchase, healthcare consum-
ers may be inclined to choose lower
cost providers if they believe
they are getting a good value in
care. In order for this approach to
be successful, the costs of such
services have to be easily and
readily available. Unfortunately,
no exhaustive database that may
be accessed by either patients or
healthcare providers listing prices
for orthopaedic services is avail-
able. Therefore, a system in which
calls are made to healthcare in-
stitutions in an attempt to obtain
price quotes has been developed
and previously published in the
literature.9,10 Using this modal-
ity, the aim of this study was
to determine the access to the
consumer price of surgical treat-
ment for end-stage ankle arthritis,
namely TAAs and ankle arthro-
desis. The second aim of the study
was to determine the variability
of the prices among institutions
and between the two different
procedures. We hypothesized
that the costs of the procedures
would not be easily accessible,
that there would be a wide vari-
ability between institutions, and
that the mean price of a TAA
would be greater than that of an
arthrodesis.
Methods
Institution Selection
Fifty orthopaedic foot and ankle
centers, 25 academic and 25 private,
were selected using the American
Orthopaedic Foot and Ankle Society
database. Twenty-five different states
were chosen to allow for regional
variations, with one academic and
one private center selected in each
state. Medical centers were consid-
ered academic if they were affiliated
with a medical school and had an
orthopaedic surgery residency pro-
gram. Medical centers were consid-
ered private if they were not involved
in teaching residents or fellows. The
academic and private institutions
were selected at random. Providers
were only selected if their public
website stated that they treat ankle
arthritis.
Script Design
A script was designed using a
consensus-based approach that
included input from all authors. In
the script, the patient is a 63-year-old
man with a history of right ankle
arthritis and who is in need of a TAA
or an ankle arthrodesis. His son is
calling on his behalf to request the
total packaged cost of the surgeries.
The patient is self-employed and will
be paying for the procedure out of
pocket. He is requesting the bundled
cost of the surgery before travelling to
the institution and scheduling a clinic
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visit with the surgeon. Additional
information was provided only if re-
quested. The current procedural ter-
minology cited if requested by the
institution were 27702 (ankle replace-
ment) and 27870 (ankle fusion). The
International Statistical Classification
of Diseases and Related Health Prob-
lems-10 code provided if requested
wasM19.071. The bundled quotewas
asked to include anesthesia, preopera-
tive care, nursing, meals, medications,
one overnight stay in hospital, im-
plants, and the surgeon’s fee.
Data Collection
Each institution was contacted up
to a maximum of 3 times to provide
an out-of-pocket cost. The first tele-
phone number used to contact the
centers was the primary number lis-
ted on its website to schedule an
appointment with the foot and ankle
surgeon. If the receptionist who
answered the phone was not able to
provide the necessary information,
they were encouraged to transfer the
caller to the hospital financial services
or billing department. If the call was
transferred, then this was still
considered a single attempt at ob-
taining the pricing information. If the
caller was provided a new number to
dial, then calling the newnumberwas
considered a second attempt. Drop-
ped calls were not considered an
attempt. If the institution stated that
they wished to e-mail information
regarding the bundled quote, then an
e-mail address was provided. This
address was created solely for this
purpose. If a reason for not being
provided with the cost information
was given, this was recorded.
Statistical Analysis
All statistical analyseswereperformed
using SAS software. An independent
t test was used to compare prices
between academic and private in-
stitutions as well as between ankle
arthrodesis and TAA. The a level was
set at 0.05.
Results
Twenty-one institutions (42%) were
able to provide a quote for an ankle
arthrodesis and a TAA. Separated by
institution type, 56% and 26% of
academic and private institutions,
respectively,were forthcomingwith a
price quote. The reason most in-
stitutions (75%) were not able to
provide the caller with the cost of the
surgery was exhaustion of the three
call attempts. The other explanation
(25%) was the patient must first be
seen at their facility and by their sur-
geons before a price may be offered.
The mean bundled price for an
ankle arthrodesis was $42,808 (SD6
26,033; range 6,227 to 92,657.09),
with the mean academic and private
center quote being $49,693 and
$29,037, respectively. No statisti-
cally significant difference was ob-
served in the cost of an arthrodesis
between an academic or private fa-
cility (P = 0.08). The mean bundled
price for a TAA was $48,944 (SD 6
25,744; range 12,750 to 112,076.17),
with the mean academic and private
institution cost being $54,446 and
$37,938, respectively. No statisti-
cally significant difference in the
price of a TAA between an academic
or private facility (P = 0.17) was
found. In addition, no difference was
observed between the bundled cost
of an ankle arthrodesis and a TAA
(P = 0.44).
Discussion
The results of this study indicate that
obtaining a cost estimate for surgical
treatment of end-stage ankle arthritis
is difficult. Confirming our hypothe-
sis, only 42% of centers were able to
provide a bundled price estimate.
As a result, a healthcare consumer
would struggle to compare pricing
between different centers. These re-
sults correlate somewhat with similar
studies available in the literature.9
Willey et al10 performed a study as-
sessing the availability of consumer
prices for bunion surgery and noted
39.7% of the clinics they contacted
were able to provide them with a
physician fee for the procedure.
However, the authors noted that
only 8.5% were able to give them a
bundled cost. A potential reason
for the variability in obtaining a
bundled quote may be the persis-
tence of the caller and willingness
for the call to be transferred to
different departments. The impor-
tance of replication studies should
not be underestimated as a minimal
amount these are performed in the
medical literature.
Themost common reason for being
unable to retrieve a quote was ex-
hausting the 3-call limit. This was
usually due to most institutions being
unprepared and disorganized with a
price request. Frequently, after the
first or second call, the caller was
referred to the facility’s financial
counselor or advisor. The call to the
financial advisor would usually
result in the caller leaving a voice-
mail or the advisor claiming that
they would call back with further
information. However, in most in-
stances, the institution never con-
tacted the caller again. This conflicts
with price transparency legislation
passed in multiple states requiring
hospitals and clinics to provide price
estimates for nonemergency proce-
dures when requested.11-13 In the
current study, a common reason for
not being able to retrieve the cost of
the procedures was insistence that
the patient must first be seen by the
facility’s own physicians. Compli-
ance with this would mean that if a
patient wishes to do any sort of price
comparison, resources and time
must first be spent travelling to and
being seen by multiple different
surgeons. Therefore, insisting that a
Niall A. Smyth, MD, et al
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patient must be seen in person may
in effect increase the burden of
healthcare cost.
A wide variation in prices between
institutions for both an ankle
arthrodesis and a TAAwas observed.
The range of prices reported for an
arthrodesis and TAA were $6,227 to
$92,657 and $12,750 to $112,076,
respectively. This is consistent with
the previous literature citing the
consumer prices for a variety of pro-
cedures including an electrocardio-
gram, total hip arthroplasty, and
hallux valgus correction.9,10,14 The
variability between facilities may be
attributed to the manner in which
hospitals and clinics report the con-
sumer price. There are three general
terms used in healthcare billing: the
charge, cost, and reimbursement.
The charge is the amount asked by a
healthcare provider for the service;
however, this is not necessarily what
the provider expects to get paid. The
reimbursement is the payment made
by a third party (usually an insur-
ance company or federal national
insurance program) for the services
provided. Cost is the expense
incurred by the provider to deliver
the healthcare service.15,16 If the
institution cited the charges of the
surgical procedure when asked for a
consumer price, this could explain
the higher prices in our study.
However, other facilities provided
costs which they stated were specific
to patients who are paying out of
pocket and it is likely that these prices
are more similar to the actual reim-
bursement accrued by the providers.
This information is of interest to
surgeons because their practice may
be discouraging patients from seek-
ing care if consumer prices are diffi-
cult to obtain or exorbitantly high.
A trend was found indicating
increased prices for an ankle arthro-
desis at an academic versus a private
institution (P = 0.08). Higher prices
for care at academic institutions has
previously been attributed to them
receiving higher reimbursement by
Medicare to compensate for their
educational mission.17 However, the
literature is conflicting regarding the
cost of care at academic versus pri-
vate hospitals, with various studies
reporting in favor of one or the
other, or concluding no difference
between the two.9,10,18,19
Although ankle arthrodesis has
been used traditionally to treat end-
stage ankle arthritis, the clinical out-
comes comparing arthrodesis to TAA
have been reported in multiple stud-
ies.20-23 With regard to comparing
quoted consumer prices for the two
procedures, our results showed no
notable difference between ankle
arthrodesis and TAA. This conclu-
sion differs from our hypothesis and
other price comparisons found in the
literature. Previous studies have
reported on price comparisons
between ankle arthrodesis and TAA
using different methods. Using the
Markov prediction model, Courville
et al24 noted that a TAA costs
$20,200 more than an ankle
arthrodesis but results in 1.7 addi-
tional quality-adjusted life years.
Nwachukwu et al25 concluded that
although direct costs were greater
with a TAA, once indirect costs were
included, TAA was associated with
cost savings.
One of the limitations of this study
is that the response rate of facilities
may differ depending on the force-
fulness and perseverance of the caller.
Thus, a real patient who wished to
find out the cost of their surgery may
not cease their inquiry after three calls
and may be more insistent with the
institution’s financial services
department. In addition, it is difficult
to draw conclusions regarding the
true price a patient may be asked to
pay for a TAA or arthrodesis with
the numbers reported in this study
because charges and expected reim-
bursement are not the same.26 Also
worth noting is the potential impact
of price transparency on reducing
healthcare expenditure, which is
questionable. Although the general
population expresses a positive
opinion on the concept of shopping
for better value health care, other
factors may be considered more
important. These include loyalty to
current providers and perception of
quality of care, which may be
directly linked to the cost of care.27
Furthermore, when patients are
offered access to price transparency,
it may be used by only a very small
percentage of the population.28
Lastly, while previous studies have
assessed the availability of consumer
prices for surgery, the importance of
replication studies should not be un-
derestimated as there are a minimal
amount these performed in the med-
ical literature. As Ioannidis29 identi-
fied in a landmark article, only 44%
of the most cited original research
studies have had their results repli-
cated. A further strength of this article
is that it simulates the experience an
actual healthcare consumer may
encounter when trying to obtain a
bundled price for surgery.
Although the current study com-
pared bundled costs between TAA
and ankle arthrodesis, additional
factors need to be considered that
could influence cost as well. Type of
insurance plan and associated de-
ductibles could affect the overall
costs for a given patient. Based on
the patient and associated co-
morbidities, the ability to perform a
surgery at an outpatient center
versus a hospital could influence
cost differences. Patient factors,
including habitus and extent of
deformity, could affect not only the
type of implant required but also
ancillary procedures necessary to
appropriately treat the pathology.
These variables may lead to costs
differences as well. These factors
were not specifically evaluated in
the present study but certainly need
to be considered as the basis of
future research.
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In conclusion, there is low avail-
ability of consumer prices for surgical
management of end-stage ankle
arthritis. Low availability inhibits a
patient’s ability to compare prices
between institutions to take advan-
tage of the wide variability in costs.
A patient may also consider that no
difference in price exists between an
academic and private institution or
between an ankle arthrodesis and a
TAA when making a choice regard-
ing their health care.
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